NxStage Medical Inc. (NASDAQ:NXTM) traded down 1.8% during mid-day trading on Friday . The stock traded as low as $21.92 and last traded at $22.11, with a volume of 123,346 shares changing hands. The stock had previously closed at $22.52.

Several equities research analysts have recently issued reports on the company. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a report on Wednesday, July 6th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $21.00 price target on shares of NxStage Medical in a report on Tuesday, May 17th. Canaccord Genuity reiterated a “buy” rating on shares of NxStage Medical in a report on Wednesday, May 4th. BTIG Research reiterated a “buy” rating and set a $27.00 price target on shares of NxStage Medical in a report on Tuesday, June 7th. Finally, Wells Fargo & Co. restated a “sell” rating on shares of NxStage Medical in a report on Thursday, May 5th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $24.50.

The firm has a 50 day moving average of $21.06 and a 200-day moving average of $17.81. The company’s market capitalization is $1.43 billion.

NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings results on Wednesday, May 4th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.03. The business earned $89.20 million during the quarter, compared to the consensus estimate of $88.40 million. During the same quarter last year, the company earned ($0.09) earnings per share. The firm’s revenue was up 12.2% compared to the same quarter last year. Equities research analysts predict that NxStage Medical Inc. will post ($0.12) earnings per share for the current year.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 1,500 shares of the stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $17.89, for a total value of $26,835.00. Following the completion of the sale, the president now directly owns 103,280 shares in the company, valued at $1,847,679.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Other large investors have made changes to their positions in the company. Morgan Stanley increased its stake in shares of NxStage Medical by 1.3% in the fourth quarter. Morgan Stanley now owns 67,174 shares of the medical device company’s stock valued at $1,472,000 after buying an additional 874 shares during the period. California State Teachers Retirement System increased its stake in shares of NxStage Medical by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 117,165 shares of the medical device company’s stock valued at $2,567,000 after buying an additional 1,869 shares during the period. New York State Common Retirement Fund increased its stake in shares of NxStage Medical by 4.1% in the fourth quarter. New York State Common Retirement Fund now owns 76,493 shares of the medical device company’s stock valued at $1,676,000 after buying an additional 3,000 shares during the period. State Board of Administration of Florida Retirement System increased its stake in shares of NxStage Medical by 9.0% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 53,686 shares of the medical device company’s stock valued at $1,176,000 after buying an additional 4,450 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of NxStage Medical by 8.3% in the fourth quarter. Rhumbline Advisers now owns 68,426 shares of the medical device company’s stock valued at $1,499,000 after buying an additional 5,240 shares during the period.

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.